SI1223918T1 - Pharmaceutical compositions comprising a hmg coa reductase inhibitor - Google Patents

Pharmaceutical compositions comprising a hmg coa reductase inhibitor

Info

Publication number
SI1223918T1
SI1223918T1 SI200030065T SI200030065T SI1223918T1 SI 1223918 T1 SI1223918 T1 SI 1223918T1 SI 200030065 T SI200030065 T SI 200030065T SI 200030065 T SI200030065 T SI 200030065T SI 1223918 T1 SI1223918 T1 SI 1223918T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutical compositions
coa reductase
reductase inhibitor
hmg coa
hmg
Prior art date
Application number
SI200030065T
Other languages
English (en)
Slovenian (sl)
Inventor
Joseph Richard Creekmore
Norman Alfred Wiggins
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1223918(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SI1223918T1 publication Critical patent/SI1223918T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200030065T 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg coa reductase inhibitor SI1223918T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0001621.2A GB0001621D0 (en) 2000-01-26 2000-01-26 Pharmaceutical compositions
PCT/GB2000/003014 WO2001054668A1 (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg reductase inhibitor
EP00953283A EP1223918B1 (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg coa reductase inhibitor

Publications (1)

Publication Number Publication Date
SI1223918T1 true SI1223918T1 (en) 2003-06-30

Family

ID=9884259

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030065T SI1223918T1 (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg coa reductase inhibitor

Country Status (48)

Country Link
US (2) US6316460B1 (cs)
EP (6) EP1223918B1 (cs)
JP (3) JP3267960B2 (cs)
KR (3) KR100388713B1 (cs)
CN (3) CN1149997C (cs)
AP (2) AP1449A (cs)
AR (3) AR025055A1 (cs)
AT (3) AT412062B (cs)
AU (5) AU738074B2 (cs)
BE (2) BE1013414A5 (cs)
BG (4) BG65234B1 (cs)
BR (2) BR0003365A (cs)
CA (3) CA2315141C (cs)
CH (2) CH700184B1 (cs)
CL (1) CL2007001807A1 (cs)
CR (3) CR6568A (cs)
CZ (3) CZ299105B6 (cs)
DE (3) DE60001371T2 (cs)
DK (3) DK200001170A (cs)
EE (3) EE05586B1 (cs)
ES (2) ES2155043B1 (cs)
FI (3) FI121365B (cs)
FR (2) FR2795324B1 (cs)
GB (3) GB0001621D0 (cs)
HK (4) HK1047052A1 (cs)
HR (3) HRP20080525A2 (cs)
HU (2) HUP0003111A3 (cs)
IL (4) IL150513A0 (cs)
IS (3) IS1940B (cs)
IT (2) ITTO20000780A1 (cs)
ME (4) ME00202B (cs)
MY (2) MY122707A (cs)
NL (2) NL1015859C2 (cs)
NO (4) NO312434B1 (cs)
NZ (2) NZ519774A (cs)
PL (2) PL196808B1 (cs)
PT (3) PT102504A (cs)
RS (1) RS50201B (cs)
RU (2) RU2264210C2 (cs)
SE (2) SE523471C2 (cs)
SI (1) SI1223918T1 (cs)
SK (2) SK283872B6 (cs)
TR (3) TR200200270T2 (cs)
TW (2) TWI228050B (cs)
UA (2) UA51853C2 (cs)
WO (2) WO2001054669A1 (cs)
YU (1) YU52902A (cs)
ZA (2) ZA200003997B (cs)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
PT1274401E (pt) † 2000-04-10 2011-12-02 Teva Pharma Composições farmacêuticas estáveis contendo ácidos 7-substituídos-3,5-di-hidroxi-heptanóicos ou ácidos 7-substituídos-3,5-di-hidroxi-heptenóicos
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
EP1911462A3 (en) * 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US7842308B2 (en) * 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
US7883721B2 (en) * 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
AU2003254914A1 (en) * 2002-08-12 2004-03-03 Kyowa Hakko Kogyo Co., Ltd. Amino acid-containing chewable
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
TW200526274A (en) * 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
CA2657076A1 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin calcium
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
PL2821067T3 (pl) * 2003-09-12 2018-02-28 Amgen Inc. Szybko rozpuszczający się preparat cynakalcetu
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
CA2546701C (en) * 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
US7244844B2 (en) * 2003-12-02 2007-07-17 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
TW200539903A (en) * 2004-03-12 2005-12-16 Smithkline Beecham Plc Pharmaceutical formulations
US7226620B2 (en) * 2004-05-04 2007-06-05 Rhodia Inc. Directly compressible tricalcium phosphate
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
CN1323665C (zh) * 2004-06-16 2007-07-04 鲁南制药集团股份有限公司 治疗高血脂症的组合物
WO2006017357A1 (en) * 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
KR20070052760A (ko) * 2004-08-06 2007-05-22 트렌스폼 파마수티컬스 인코퍼레이티드 신규한 페노피브레이트 제제 및 관련된 치료방법
JP2008526781A (ja) * 2005-02-22 2008-07-24 テバ ファーマシューティカル インダストリーズ リミティド ロスバスタチンの製造
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
RU2303980C2 (ru) * 2005-06-03 2007-08-10 ОАО "Щелковский витаминный завод" Лекарственная форма с антиагрегационным действием и способ ее изготовления
MX2008001597A (es) * 2005-08-04 2008-04-04 Transform Pharmaceuticals Inc Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento.
US7868169B2 (en) * 2005-08-16 2011-01-11 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin intermediate
CN101262847B (zh) 2005-09-12 2010-11-24 埃科特莱茵药品有限公司 包含嘧啶-磺酰胺的稳定性医药组合物
CN101300010B (zh) * 2005-10-31 2012-06-06 兴和株式会社 光稳定性优异的医药制剂
AU2006329006B2 (en) * 2005-12-20 2013-02-28 Lek Pharmaceuticals D.D. Pharmaceutical composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
EP2024341B1 (en) * 2006-05-03 2015-12-02 MSN Laboratories Private Limited Novel process for statins and its pharmaceutically acceptable salts thereof
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
EP2086945B1 (en) * 2006-10-09 2016-01-06 MSN Laboratories Private Limited Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
JP2010523659A (ja) * 2007-04-09 2010-07-15 サイドース・エルエルシー スタチン類と抗肥満症薬との組み合わせ
WO2008124122A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
CN101336920B (zh) * 2007-07-05 2013-06-05 江苏正大天晴药业股份有限公司 一种稳定的药物组合物
EP2285353A1 (en) * 2008-01-30 2011-02-23 Lupin Limited Modified release formulations of hmg coa reductase inhibitors
WO2009112870A1 (en) * 2008-03-11 2009-09-17 Belupo-Lijekovi I Kozmetika D.D. Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer
CA2725052C (en) 2008-05-27 2014-09-16 Changzhou Pharmaceutical Factory Co., Ltd. Preparation method of rosuvastatin calcium and its intermediates
EP2320876A2 (en) * 2008-06-13 2011-05-18 Pfizer Inc. Hydroxypropyl cellulose capsule shell
ES2657416T3 (es) * 2008-06-27 2018-03-05 Krka, Torvarna Zdravil, D.D., Novo Mesto Composición farmacéutica que comprende una estatina
EP2306982B1 (en) * 2008-06-27 2015-01-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical compositions of rosuvastatin calcium
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
WO2010089770A2 (en) 2009-01-19 2010-08-12 Msn Laboratories Limited Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
TR200902077A2 (tr) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stabil rosuvastatin kompozisyonları
US8470805B2 (en) * 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
TR200904341A2 (tr) 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
WO2011018185A2 (en) 2009-08-13 2011-02-17 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof
CN101766578B (zh) * 2010-02-09 2011-06-08 鲁南贝特制药有限公司 一种含瑞舒伐他汀钙的片剂及其制备工艺
TR201009397A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
WO2011139256A2 (en) 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
US9399064B2 (en) * 2011-04-12 2016-07-26 Sawai Pharmaceutical Co., Ltd. Pitavastatin-containing preparation and method for producing same
WO2012160352A1 (en) 2011-05-20 2012-11-29 Astrazeneca Uk Limited Pharmaceutical composition of rosuvastatin calcium
RU2508109C2 (ru) * 2011-05-27 2014-02-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения нарушений липидного обмена
EP2851075B1 (en) * 2012-05-14 2021-12-01 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoylmorphinan derivative
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
US20160045497A1 (en) 2013-03-12 2016-02-18 Lg Life Sciences Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
RO129060B1 (ro) 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
RU2547574C2 (ru) * 2013-07-09 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Лекарственная форма гиполипидемического действия и способ ее изготовления
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
WO2016076280A1 (ja) * 2014-11-11 2016-05-19 塩野義製薬株式会社 光に対して不安定な薬物を含有する多層錠剤
JP2016169198A (ja) * 2015-03-13 2016-09-23 大原薬品工業株式会社 ロスバスタチンカルシウムを含有する錠剤
JP6095176B2 (ja) * 2015-04-24 2017-03-15 大原薬品工業株式会社 ロスバスタチンカルシウムの光安定性が向上したフィルムコーティング錠剤
CN108472249A (zh) 2015-10-23 2018-08-31 林德拉有限公司 用于治疗剂缓释的胃驻留系统及其使用方法
EP4302817A3 (en) 2015-12-08 2024-02-21 Lyndra Therapeutics, Inc. Geometric configurations for gastric residence systems
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
US12109305B2 (en) 2016-05-27 2024-10-08 Lyndra Therapeutics, Inc. Materials architecture for gastric residence systems
EP3518902A4 (en) 2016-09-30 2020-07-08 Lyndra, Inc. GASTRIC RESIDENCE SYSTEMS FOR LONG-TERM ADMINISTRATION OF ADAMANTANE CLASS MEDICINES
CN107913257A (zh) * 2016-10-10 2018-04-17 北京阜康仁生物制药科技有限公司 一种包含瑞舒伐他汀钙的药物组合物及其制备方法
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
US12023406B2 (en) 2017-06-09 2024-07-02 Lyndra Therapeutics, Inc. Gastric residence systems with release rate-modulating films
JP2018027987A (ja) * 2017-11-24 2018-02-22 共和薬品工業株式会社 医薬組成物
CN112274487A (zh) * 2019-07-25 2021-01-29 北京福元医药股份有限公司 一种瑞舒伐他汀钙药物制剂
CN110638743B (zh) * 2019-10-25 2023-03-28 乐普制药科技有限公司 一种含布立西坦的组合物
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
GB2622822A (en) 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2262229A (en) * 1939-06-24 1941-11-11 Interchem Corp Pigment and method of preparation
GB653026A (en) 1947-07-02 1951-05-09 Merck & Co Inc Vitamin preparations
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4868185A (en) * 1987-12-10 1989-09-19 Warner-Lambert Company 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4929620A (en) * 1987-12-10 1990-05-29 Warner-Lambert Company 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
NO890521L (no) 1988-02-25 1989-08-28 Bayer Ag Substituerte pyrimidiner.
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
EP0367895A1 (en) * 1988-10-06 1990-05-16 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
ES2064887T3 (es) 1990-09-13 1995-02-01 Akzo Nobel Nv Composiciones quimicas solidas estabilizadas.
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
RU2098411C1 (ru) * 1991-08-02 1997-12-10 Иституто Лусо Фармако д Италия С.п.А. Производные пиримидина, способ их получения, фармацевтическая композиция на их основе
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5478832A (en) 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
SG45369A1 (en) 1993-01-19 1998-10-16 Warner Lambert Co Stable oral ci-981 formulation and process of preparing same
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
EP0814782B1 (en) * 1995-12-22 2002-11-27 Kowa Company Ltd. Pharmaceutical composition stabilized with a basic agent
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
PL344586A1 (en) 1998-06-05 2001-11-05 Warner Lambert Co Stabilization of compositions containing ace inhibitors using magnesium oxide
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
US6150410A (en) 1999-02-04 2000-11-21 Abbott Laboratories pH independent extended release pharmaceutical formulation
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB0000710D0 (en) * 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
AR022462A1 (es) * 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
EP1253921A4 (en) 2000-01-28 2004-10-13 Merck & Co Inc TREATMENT AND PROPHYLAXIS OF PROSTATE CANCER WITH COX-2 SELECTIVE INHIBITORS

Also Published As

Publication number Publication date
ES2171123B1 (es) 2003-11-16
CH700184B1 (de) 2010-07-15
FR2804025A1 (fr) 2001-07-27
CL2007001807A1 (es) 2008-01-18
AU2000264559A1 (en) 2001-08-07
HK1040936A1 (zh) 2002-06-28
DE10038110B4 (de) 2006-06-29
DK200001170A (da) 2001-01-27
BG66168B1 (bg) 2011-10-31
YU52902A (sh) 2006-01-16
CA2315141A1 (en) 2001-07-26
MY123650A (en) 2006-05-31
NO20003968L (no) 2001-07-27
KR100388713B1 (ko) 2003-06-25
SK11792000A3 (sk) 2001-12-03
CA2313783A1 (en) 2000-10-16
PL341855A1 (en) 2001-07-30
HUP0003111A3 (en) 2003-03-28
EE05586B1 (et) 2012-10-15
JP2001206847A (ja) 2001-07-31
HRP20020632A2 (en) 2004-12-31
IL147870A (en) 2003-10-31
NL1015858C2 (nl) 2001-07-27
IL150513A0 (en) 2003-02-12
TR200201888T2 (tr) 2002-11-21
HUP0003110A3 (en) 2003-02-28
FI20001749L (fi) 2001-07-27
PT102503B (pt) 2004-02-27
ZA200003997B (en) 2000-08-14
KR20000072135A (ko) 2000-12-05
IL187416A0 (en) 2008-02-09
CR6568A (es) 2004-03-05
EE05221B1 (et) 2009-10-15
UA51853C2 (uk) 2002-12-16
AU781269B2 (en) 2005-05-12
CN101028268A (zh) 2007-09-05
CZ298411B6 (cs) 2007-09-26
ATE232088T1 (de) 2003-02-15
IS8620A (is) 2007-03-07
CA2315141C (en) 2009-08-18
ME00202B (me) 2010-10-10
EP1223918B1 (en) 2003-02-05
US6316460B1 (en) 2001-11-13
WO2001054668A1 (en) 2001-08-02
CN1149997C (zh) 2004-05-19
AU781269C (en) 2006-11-30
GB0019028D0 (en) 2000-09-27
CH691347A5 (de) 2001-07-13
FI20001750L (fi) 2001-07-27
EP1251831A1 (en) 2002-10-30
IL150513A (en) 2012-12-31
JP4800467B2 (ja) 2011-10-26
ME00191B (me) 2010-10-10
EE200200052A (et) 2003-04-15
DE60001371T2 (de) 2004-01-22
HRP20020632B1 (en) 2010-12-31
KR20030036492A (ko) 2003-05-09
FI121365B (fi) 2010-10-29
GB0001621D0 (en) 2000-03-15
GB2358582B (en) 2004-09-29
NO2010005I1 (no) 2010-05-03
ATA13602000A (de) 2004-02-15
AU2005202392B2 (en) 2008-11-20
EP2133070A1 (en) 2009-12-16
AU2005202392A1 (en) 2005-06-30
HUP0003110A2 (hu) 2001-05-28
AU6580000A (en) 2001-08-07
HU0003111D0 (en) 2000-10-28
SE0002827L (sv) 2001-07-27
DE10038110A1 (de) 2001-08-23
HU0003110D0 (en) 2000-10-28
IS6254A (is) 2002-01-29
AU5184100A (en) 2001-08-02
CN1282581A (zh) 2001-02-07
ES2171123A1 (es) 2002-08-16
NZ531474A (en) 2007-04-27
HRP20020097B1 (hr) 2010-12-31
PT102503A (pt) 2000-12-29
CZ299105B6 (cs) 2008-04-23
TR200701171T2 (tr) 2007-04-24
AP2002002409A0 (en) 2002-03-31
JP3267960B2 (ja) 2002-03-25
GB2358583B (en) 2002-02-06
RU2002122752A (ru) 2004-03-10
RS50201B (sr) 2009-07-15
SE523471C2 (sv) 2004-04-20
PT1223918E (pt) 2003-06-30
KR100698333B1 (ko) 2007-03-23
DK178242B1 (da) 2015-09-28
JP2007182452A (ja) 2007-07-19
MY122707A (en) 2006-04-29
FI20001750A0 (fi) 2000-08-04
HK1036935A1 (en) 2002-01-25
HK1047052A1 (zh) 2003-02-07
PL196808B1 (pl) 2008-02-29
CA2639407C (en) 2011-09-13
TWI228050B (en) 2005-02-21
SK283872B6 (sk) 2004-03-02
FR2795324B1 (fr) 2002-05-17
JP2001206877A (ja) 2001-07-31
HUP0003111A2 (hu) 2002-02-28
BE1013414A5 (fr) 2001-12-04
CN100528161C (zh) 2009-08-19
NO312434B1 (no) 2002-05-13
GB2358582A (en) 2001-08-01
JP4800988B2 (ja) 2011-10-26
IS1940B (is) 2004-07-16
AP1879A (en) 2008-08-14
CN1319396A (zh) 2001-10-31
ZA200003998B (en) 2000-08-14
AT412063B (de) 2004-09-27
AU5184200A (en) 2001-08-02
BR0003364A (pt) 2001-09-18
BG106926A (bg) 2003-04-30
SE0002827D0 (sv) 2000-08-04
AP1449A (en) 2005-07-28
CA2639407A1 (en) 2001-07-26
CR10114A (es) 2008-08-21
ATA13612000A (de) 2004-02-15
RU2264210C2 (ru) 2005-11-20
EP2266540A1 (en) 2010-12-29
GB0019029D0 (en) 2000-09-27
AR025055A1 (es) 2002-11-06
SE0002826D0 (sv) 2000-08-04
MEP33708A (hr) 2010-10-10
FI121589B (fi) 2011-01-31
GB2358583A (en) 2001-08-01
NL1015859A1 (nl) 2001-07-27
BG110353A (en) 2009-09-30
HK1200368A1 (en) 2015-08-07
HK1040936B (zh) 2010-06-11
NO20003967L (no) 2001-07-27
DK1223918T3 (da) 2003-04-28
CR6687A (es) 2005-07-18
TW553749B (en) 2003-09-21
SE0002826L (sv) 2001-07-27
IS2805B (is) 2012-09-15
AR060248A2 (es) 2008-06-04
BG106393A (en) 2002-07-31
DE60001371D1 (de) 2003-03-13
EE200900047A (et) 2011-04-15
HK1048950A1 (zh) 2003-04-25
YU5202A (sh) 2004-12-31
IL147870A0 (en) 2002-08-14
BE1013413A3 (fr) 2001-12-04
MEP33808A (hr) 2010-10-10
RU2206324C1 (ru) 2003-06-20
BR0003365A (pt) 2001-09-18
SK11782000A3 (sk) 2001-12-03
CZ290167B6 (cs) 2002-06-12
EP2018853A1 (en) 2009-01-28
EP2774609A1 (en) 2014-09-10
NO20003967D0 (no) 2000-08-04
AT412062B (de) 2004-09-27
KR20010077840A (ko) 2001-08-20
AP2002002591A0 (en) 2002-09-30
AU738074B2 (en) 2001-09-06
NO327554B1 (no) 2009-08-10
FR2804025B1 (fr) 2002-08-23
CZ20002884A3 (cs) 2001-09-12
DK200001171A (da) 2001-07-27
ES2155043B1 (es) 2001-12-01
CZ20002883A3 (cs) 2000-10-11
BG65234B1 (bg) 2007-09-28
ITTO20000779A1 (it) 2002-02-04
HU222578B1 (hu) 2003-08-28
ITTO20000779A0 (it) 2000-08-04
DE10038108A1 (de) 2001-08-02
PT102504A (pt) 2001-07-31
TR200200270T2 (tr) 2002-06-21
NL1015859C2 (nl) 2001-10-16
ITTO20000780A1 (it) 2000-11-04
NO20003968D0 (no) 2000-08-04
ES2155043A1 (es) 2001-04-16
HRP20020097A2 (en) 2002-06-30
UA77156C2 (en) 2006-11-15
PL341853A1 (en) 2001-01-29
EP1223918A1 (en) 2002-07-24
WO2001054669A1 (en) 2001-08-02
NO20071303L (no) 2001-07-27
NO327675B1 (no) 2009-09-07
EE200200411A (et) 2003-12-15
NZ519774A (en) 2004-04-30
BG66159B1 (bg) 2011-09-30
FI20001749A0 (fi) 2000-08-04
US6548513B1 (en) 2003-04-15
AU2005202392C1 (en) 2016-06-02
SE523481C2 (sv) 2004-04-20
FR2795324A1 (fr) 2000-12-29
AR023624A1 (es) 2002-09-04
CA2313783C (en) 2002-03-12
HK1036934A1 (en) 2002-01-25
HRP20080525A2 (en) 2008-12-31
EE04990B1 (et) 2008-04-15
FI111806B (fi) 2003-09-30
IS6480A (is) 2002-07-23
FI20105657L (fi) 2010-06-10

Similar Documents

Publication Publication Date Title
IL187416A0 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING A HMG CoA REDUCTASE INHIBITOR
HUP0104258A3 (en) Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor
HUP0301087A3 (en) Oral pharmaceutical composition comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
IL152077A0 (en) Pharmaceutical compositions comprising fluvastatin
AU2001250420A1 (en) Pharmaceutical compositions
AU2001274307A1 (en) Pharmaceutical compositions
IL154977A0 (en) Statins (hmg-coa reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
GB0009584D0 (en) Pharmaceutical compositions
AU2002310798A1 (en) Pharmaceutical compositions comprising a hmg-coa reductase inhibitor
AU8576801A (en) Pharmaceutical compositions
AU1390002A (en) Pharmaceutical compositions
AU2001273919A1 (en) Pharmaceutical compositions
EP1372616A4 (en) STABLE PHARMACEUTICAL COMPOSITION BASED ON PRAVASTATIN
GB0009613D0 (en) Pharmaceutical compositions
IL149524A0 (en) HMG-CoA REDUCTASE INHIBITOR EXTENDED RELEASE FORMULATIONS
IL144285A0 (en) Pharmaceutical compositions containing a vasopeptidase inhibitor
HUP0301728A3 (en) Hmg-coa reductase inhibiting pharmaceutical compositions and their use
AU2003252358A1 (en) MEDICINAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR
AU2001285737A1 (en) Pharmaceutical compositions
HK1061653A (en) A stable pharmaceutical composition of pravastatin
HU0102982D0 (en) Synergic pharmaceutical composition
AUPQ875300A0 (en) A pharmaceutical composition
HK1053420A (en) Pharmaceutical compositions comprising fluvastatin
HK1036935B (en) Pharmaceutical compositions
HK1036934B (zh) 药物组合物